Latest news
Gilead second-quarter sales rise 8%, beating Wall Street estimates - ET PharmaET Pharma · Wed, 05 Aug 2026 19:57:15 GMTGILD Q2 Deep Dive: Pipeline Expansion and HIV Portfolio Drive Growth Amid Margin Pressure - StockStoryStockStory · Wed, 05 Aug 2026 16:57:13 GMTGILD Q2 Earnings Beat on HIV and Trodelvy Growth, Product Sales Outlook Raised - Yahoo FinanceYahoo Finance · Wed, 05 Aug 2026 15:22:00 GMTGILD: Q2 2026 base business grew 10% year-over-year, driven by HIV, Trodelvy, and Livdelzi - TradingViewTradingView · Tue, 04 Aug 2026 20:07:41 GMTHow Investors May Respond To Gilead Sciences (GILD) EMA Backing Trodelvy Plus Keytruda In First-Line TNBC - webull.comwebull.com · Fri, 31 Jul 2026 21:36:45 GMTGilead: Buy The Distortion Before Q2 Clears It Up - Seeking AlphaSeeking Alpha · Thu, 30 Jul 2026 07:00:00 GMTIs Gilead Sciences (GILD) Overvalued Following Its Trodelvy Europe Expansion Win? - SahmSahm · Tue, 28 Jul 2026 07:00:00 GMT